Subtopic Deep Dive
Interstitial Lung Disease in Dermatomyositis
Research Guide
What is Interstitial Lung Disease in Dermatomyositis?
Interstitial lung disease (ILD) in dermatomyositis refers to pulmonary fibrosis and inflammation occurring in dermatomyositis patients, often rapidly progressive and linked to anti-MDA5 antibodies.
ILD affects 20-40% of dermatomyositis cases, with anti-MDA5 positivity predicting rapid progression (Sato et al., 2009; 592 citations). Prevalence and outcomes were detailed in early cohorts (Marie et al., 2002; 484 citations). Over 10 key papers since 2002 address autoantibodies, imaging, and therapies.
Why It Matters
ILD causes over 40% mortality in dermatomyositis, demanding early anti-MDA5 screening for risk stratification (Sato et al., 2005; 725 citations). Tofacitinib shows efficacy in anti-MDA5 ILD cases (Chen et al., 2019; 357 citations), while tacrolimus-cyclophosphamide-glucocorticoid triples survival in prospective trials (Tsuji et al., 2019; 340 citations). These findings guide immunosuppression, reducing ventilator needs in amyopathic dermatomyositis.
Key Research Challenges
Rapid progression prediction
Anti-MDA5 ILD advances fatally within months despite therapy (Sato et al., 2009). Biomarker levels fail to consistently forecast decline (Betteridge et al., 2015). Imaging patterns vary, complicating prognosis.
Optimal immunosuppression
Triple therapy improves survival but relapse rates exceed 30% (Tsuji et al., 2019). Tofacitinib aids refractory cases yet lacks randomized data (Chen et al., 2019). Anti-ARS heterogeneity alters ILD timing (Hamaguchi et al., 2013).
Autoantibody specificity
CADM-140/MDA5 detection via immunoprecipitation misses variants (Sato et al., 2005). Myositis-specific autoantibodies overlap with other ILDs (Marie et al., 2002). Standardization lags for clinical use.
Essential Papers
Myositis‐specific autoantibodies: an important tool to support diagnosis of myositis
Zoë Betteridge, NJ McHugh · 2015 · Journal of Internal Medicine · 1.0K citations
Abstract The idiopathic inflammatory myopathies are characterized by muscle weakness, skin disease and internal organ involvement. Autoimmunity is known to have a role in myositis pathogenesis, and...
Autoantibodies to a 140‐kd polypeptide, CADM‐140, in Japanese patients with clinically amyopathic dermatomyositis
Shinji Sato, Michito Hirakata, Masataka Kuwana et al. · 2005 · Arthritis & Rheumatism · 725 citations
Abstract Objective To identify novel autoantibodies specific for dermatomyositis (DM), especially those specific for clinically amyopathic DM (C‐ADM). Methods Autoantibodies were analyzed by immuno...
RNA helicase encoded by melanoma differentiation–associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease
Shinji Sato, Kana Hoshino, Takashi Satoh et al. · 2009 · Arthritis & Rheumatism · 592 citations
Abstract Objective To identify the autoantigen recognized by the autoantibody that is associated with clinically amyopathic dermatomyositis (C‐ADM) and rapidly progressive interstitial lung disease...
Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
E. J. Kim, Brett M. Elicker, Fabien Maldonado et al. · 2009 · European Respiratory Journal · 577 citations
Interstitial lung disease is a common manifestation of rheumatoid arthritis; however, little is known about factors that influence its prognosis. The aim of the present study was to determine wheth...
Interstitial lung disease in polymyositis and dermatomyositis
I. Marie, É. Hachulla, P. Chérìn et al. · 2002 · Arthritis Care & Research · 484 citations
Abstract Objectives To assess prevalence, characteristics, and long‐term outcome of interstitial lung disease (ILD) in polymyositis (PM) and dermatomyositis (DM). To determine predictive variables ...
A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy
Minoru Satoh, Shin Tanaka, Angela Ceribelli et al. · 2015 · Clinical Reviews in Allergy & Immunology · 398 citations
Pathogenesis of Systemic Sclerosis
Debendra Pattanaik, Monica Brown, Bradley Postlethwaite et al. · 2015 · Frontiers in Immunology · 393 citations
Systemic scleroderma (SSc) is one of the most complex systemic autoimmune diseases. It targets the vasculature, connective tissue-producing cells (namely fibroblasts/myofibroblasts), and components...
Reading Guide
Foundational Papers
Start with Sato et al. (2005; 725 citations) for CADM-140 discovery in amyopathic DM, then Sato et al. (2009; 592 citations) linking MDA5 to RP-ILD, and Marie et al. (2002; 484 citations) for PM/DM ILD prevalence.
Recent Advances
Study Tsuji et al. (2019; 340 citations) for triple therapy efficacy and Chen et al. (2019; 357 citations) for tofacitinib in refractory cases. Betteridge et al. (2015; 1019 citations) updates myositis autoantibodies.
Core Methods
Immunoprecipitation detects anti-MDA5 (Sato et al., 2005). HRCT classifies patterns (Kim et al., 2009). Cohort analysis predicts outcomes (Hamaguchi et al., 2013).
How PapersFlow Helps You Research Interstitial Lung Disease in Dermatomyositis
Discover & Search
Research Agent uses searchPapers for 'anti-MDA5 dermatomyositis ILD' yielding Sato et al. (2009; 592 citations), then citationGraph maps 725+ citing works from Sato et al. (2005), and findSimilarPapers expands to Tsuji et al. (2019). exaSearch drills into multicenter trials.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival curves from Tsuji et al. (2019), verifyResponse with CoVe cross-checks anti-MDA5 prevalence against Sato et al. (2009), and runPythonAnalysis plots antibody titer vs. ILD progression from cohort data using pandas/matplotlib. GRADE grading scores triple therapy evidence as moderate quality.
Synthesize & Write
Synthesis Agent detects gaps in post-tofacitinib relapse data, flags contradictions between CADM-140 and MDA5 definitions (Sato et al., 2005 vs. 2009), and uses latexEditText with latexSyncCitations to draft reviews citing 10 papers, then latexCompile generates PDF. exportMermaid visualizes therapy outcome flowcharts.
Use Cases
"Extract survival stats from anti-MDA5 ILD trials"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Tsuji 2019) → runPythonAnalysis (pandas survival curves) → matplotlib plot of 1-year survival rates.
"Draft LaTeX review on ILD therapies in DM"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro) → latexSyncCitations (10 papers) → latexCompile → PDF with anti-MDA5 therapy table.
"Find code for MDA5 antibody ELISA analysis"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → R script for titer-ILD correlation from Sato et al. datasets.
Automated Workflows
Deep Research workflow scans 50+ papers via citationGraph from Sato et al. (2009), structures ILD prevalence report with GRADE scores. DeepScan's 7-steps verify anti-MDA5 therapy claims across Tsuji (2019) and Chen (2019) using CoVe checkpoints. Theorizer generates hypotheses on ILD-myositis pathways from autoantibody clusters.
Frequently Asked Questions
What defines ILD in dermatomyositis?
ILD manifests as ground-glass opacities and fibrosis on HRCT in DM patients, often without myositis (Marie et al., 2002). Anti-MDA5 positivity marks rapid progression (Sato et al., 2009).
What are main detection methods?
Immunoprecipitation identifies CADM-140/MDA5 antibodies (Sato et al., 2005). HRCT patterns predict usual interstitial pneumonia-like courses (Kim et al., 2009).
What are key papers?
Sato et al. (2005; 725 citations) found CADM-140 in amyopathic DM. Sato et al. (2009; 592 citations) linked MDA5 to RP-ILD. Tsuji et al. (2019; 340 citations) validated triple therapy.
What open problems exist?
Relapse after immunosuppression persists (Tsuji et al., 2019). Tofacitinib RCTs are absent (Chen et al., 2019). Autoantibody quantification needs standardization.
Research Inflammatory Myopathies and Dermatomyositis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Interstitial Lung Disease in Dermatomyositis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers